Pfizer Inc
NYSE: PFE
$26.02
-$0.70 (-2.6%)
Closing Price on November 14, 2024
PFE Articles
The April 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
Last Updated:
As of the most recently reported period, short sellers favored Pfizer, Apple and Intel above all other Dow stocks.
Published:
Last Updated:
Here is a slate of 15 companies that most retirees likely would want to own in their portfolio now, including AT&T, Boeing, Pfizer and Walmart.
Published:
Last Updated:
The March 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased, with two major movers in the group.
Published:
Last Updated:
As of the most recently reported period, short sellers favored Pfizer, Apple and Intel above all other Dow stocks.
Published:
Last Updated:
Sangamo Therapeutics shares jumped on Tuesday after the company announced interim data from its midstage hemophilia trial in collaboration with Pfizer.
Published:
Last Updated:
According to Credit Suisse, Pfizer investors might be getting to make up some of that relative underperformance of late.
Published:
Last Updated:
The March 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased, with two major movers in the group.
Published:
Last Updated:
As of the most recently reported period, short sellers favored Pfizer, Apple and Intel above all other Dow stocks. Many others saw sizable increases in their short interest.
Published:
Last Updated:
Stock buybacks have come under more scrutiny by the public and politicians in recent years, but companies still aggressively are buying back shares of their own stock.
Published:
Last Updated:
These five top stocks, all rated Buy at Merrill Lynch, come with outstanding dividends and have good growth prospects.
Published:
Last Updated:
Gene therapy may become the next frontier for drug companies seeking to make billions of dollars improving or even curing certain diseases.
Published:
Last Updated:
Pfizer is looking to collaborate with Vivet on the development of its proprietary treatment for Wilson disease.
Published:
Last Updated:
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased, with one major exception.
Published:
Last Updated:
Judging by the most shorted stocks traded on the New York Stock Exchange between the February 15 and February 28 settlement dates, those sellers were cautious overall, as moves were mixed and...
Published:
Last Updated: